Drug Profile
Research programme: FAAH inhibitors - sanofi-aventis
Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Cannabinoids
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder; Pain
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 09 Jul 2003 Preclinical trials in Anxiety disorders in France (unspecified route)
- 09 Jul 2003 Preclinical trials in Depression in France (unspecified route)